文献速递间质性肺疾病

吸入曲前列尼尔治疗特发性肺纤维化的TETON-1与TETON-2试验合并结果

Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2026-09-23

TETON-1和TETON-2是两项重复的3期双盲试验,共1191例IPF患者随机接受吸入曲前列尼尔或安慰剂。52周时曲前列尼尔组FVC中位变化为-45.4 ml,安慰剂组为-161.7 ml,组间差异111.8 ml(95%CI 79.7-144.0,p<0.0001),药物延缓肺功能下降并延迟临床恶化。

要点

  • 吸入曲前列尼尔52周延缓IPF患者FVC下降,组间差异111.8 ml。
  • 药物在6项次要终点中5项优于安慰剂,包括临床恶化时间和IPF急性加重时间。
  • 咳嗽是最常见的不良事件,死亡事件曲前列尼尔组41例(6.9%)对安慰剂组56例(9.4%)。

核心结论

  • 吸入曲前列尼尔在52周内减缓IPF患者肺功能下降速度,延迟临床恶化和IPF急性加重,并在DLCO和生活质量方面显示获益。
  • 结果支持在IPF患者中使用吸入曲前列尼尔。

研究设计与样本

  • TETON-1和TETON-2为两项重复的3期双盲试验,IPF患者随机接受吸入曲前列尼尔或安慰剂。
  • 共有1191例患者随机分组并接受至少一剂曲前列尼尔(597例)或安慰剂(594例)。
  • 主要终点为第52周绝对用力肺活量(FVC)变化。

主要发现

  • 曲前列尼尔组FVC自基线中位变化为-45.4 ml(95%CI -73.8至-23.1),安慰剂组为-161.7 ml(95%CI -194.5至-134.1)。
  • 52周时组间FVC差异为111.8 ml(95%CI 79.7至144.0,p<0.0001)。
  • 曲前列尼尔在6项次要疗效终点中的5项优于安慰剂,包括首次临床恶化时间、首次IPF急性加重时间、K-BILD变化、ppDLCO和ppFVC。
  • 吸入曲前列尼尔组死亡41例(6.9%),安慰剂组死亡56例(9.4%)。
  • 咳嗽是最常见的不良事件。

临床怎么用

  • 对于IPF患者,可考虑使用吸入曲前列尼尔以减缓FVC下降并延迟临床恶化。
  • 用药期间应关注咳嗽这一最常见不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inhaled treprostinil has been shown to slow the rate of loss of lung function in IPF patients in two independent studies. A detailed analysis of the fully integrated results of both studies will provide more precise and robust estimates of the drug's efficacy in IPF. METHODS: TETON-1 and TETON-2 were two replicate phase 3 double-blind trials, where patients with IPF were randomized to inhaled treprostinil or placebo. The primary endpoint was change in absolute forced vital capacity (FVC) at week 52. Secondary outcomes were time to clinical worsening, time to IPF exacerbation, survival, percent predicted FVC (ppFVC), quality of life and percent predicted diffusing capacity (ppDLCO) by 52 weeks. RESULTS: There were 1191 patients who underwent randomization and received at least one dose of treprostinil (597 patients) or placebo (594 patients) across both trials. Median change from baseline in FVC was -45.4 ml (95% CI, -73.8 to -23.1) in the treprostinil group and -161.7 ml (95% CI, -194.5 to -134.1) in the placebo group (between-group difference 111.8 ml (95% CI, 79.7 to 144.0, p < 0.0001) at 52 weeks. Treprostinil demonstrated superiority to placebo in five of six secondary efficacy endpoints including: time to first clinical worsening, time to first IPF exacerbation, change from baseline in the K-BILD, ppDLCO, and ppFVC. There were 41 (6.9%) deaths in the inhaled treprostinil group versus 56 (9.4%) deaths in the placebo group. Cough was the most common adverse event. CONCLUSIONS: Inhaled treprostinil slowed the rate of lung function loss, delayed clinical worsening and IPF exacerbations, and demonstrated benefits in DLCO and quality of life over 52 weeks. The results support the use of inhaled treprostinil in patients with IPF.(Funded by United Therapeutics Corp; ClinicalTrials.gov number, NCT04708782 for TETON-1 and NCT05255991 for TETON-2).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Nathan SD, Smith P, Deng C, et al. Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2026. PMID: 42776606. doi:10.1093/ajrccm/aamag507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。